That's just not how it works, Stormer. An industry doesn't change it's MO, just because some tech/bio investors in Oz are getting antsy about their holdings. In my first post on BGT, I likened the agri industry to pharmaceuticals in the sense it can be slow moving. I've seen this happen first hand, even with fairly low risk tech, like new breeds of wheat, barley, canola etc.
Any new molecule requires a large body of evidence and numerous field trials with potential clients. Major clients then need to model the new molecule into their product mix, estimate new and cannibalised cash flows, potential market size, legal risk, enviro/ecosystem impact, liaise with agronomists/scientists and their own clients, plus lots more.
If they can pull off a basic MOU/collaboration style agreement in the months ahead, that will set the scene for a more commercial arrangement, should the data stack-up. You'd be looking at 2020, earliest, for that in my view, assuming they get evaluations up and running in the next few months. Price wise, I'd be expecting a decent gap-up once they announce a credible relationship with a major and then maybe a lull for a while (unless further collabs are announced); once again, with some shareholders getting frustrated with the natural process and time it takes.
BGT Price at posting:
13.5¢ Sentiment: None Disclosure: Held
